Founders Capital Management Nektar Therapeutics Transaction History
Founders Capital Management
- $154 Million
- Q2 2024
A detailed history of Founders Capital Management transactions in Nektar Therapeutics stock. As of the latest transaction made, Founders Capital Management holds 700 shares of NKTR stock, worth $910. This represents 0.0% of its overall portfolio holdings.
Number of Shares
700
Previous 700
-0.0%
Holding current value
$910
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NKTR
# of Institutions
140Shares Held
135MCall Options Held
32.8KPut Options Held
55.5K-
Deep Track Capital, LP Greenwich, CT17.9MShares$23.2 Million0.73% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$19.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$16.9 Million0.0% of portfolio
-
Samlyn Capital, LLC New York, NY9.46MShares$12.3 Million0.21% of portfolio
-
Eventide Asset Management, LLC Boston, MA7.53MShares$9.79 Million0.16% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $244M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...